Initiating Treatment
Active Resources: 10
Image Library
-
2/20/2019 (reviewed: 2/20/2019)
Antiretroviral Guidelines
-
2/14/2019
-
10/27/2017
Clinical Reference Tools
-
12/11/2018
Online Training
-
10/20/2017
-
8/23/2017
-
9/15/2016
Slide Sets
-
4/28/2017
Toolkits
-
5/17/2016 (reviewed: 2/20/2019)
Charts, Tables & Posters
-
1/28/2015
Archive Resources: 6
Patient Information
-
9/29/2013 (reviewed: 2/24/2017)
-
1/1/2005
Fact Sheets
-
6/1/2013
Charts, Tables & Posters
-
6/1/2013 (reviewed: 1/11/2017)
Antiretroviral Guidelines
-
3/5/2012
Self-Study Materials
-
3/1/2010
Articles: 5
-
FDA Approves 2-Drug Combination of Dolutegravir + Lamivudine
In April 2019, the U.S. Food and Drug Administration approved a combination pill comprising the integrase inhibitor dolutegravir (DTG), 50 mg, and the NRTI lamivudine (3TC), 300 mg, for use as a complete ARV regimen for initial HIV treatment of patients. The approval specifies...
-
Immediate ART Initiation: Guide for Clinicians
Immediate antiretroviral therapy (ART) refers to starting HIV treatment as soon as possible after the diagnosis of HIV infection, preferably on the first clinic visit (and even on the same day the HIV diagnosis is made). This strategy also is known as "rapid ART," "same-day ART," and "treatment...
-
Doravirine in Initial Therapy: DRIVE-AHEAD Study
Doravirine (DOR) is an investigational NNRTI that currently is being developed in a coformulation with TDF and FTC. A Phase 3 comparison of DOR + 2 NRTIs (87% of study subjects were given TDF/FTC) and DRV/r + 2 NRTIs in initial therapy was presented at CROI earlier this year (DRIVE-FORWARD); the...
-
Bictegravir in Initial Therapy
Bictegravir (BIC) is an investigational integrase inhibitor that is being studied as part of a coformulation with tenofovir alafenamide (TAF) and emtricitabine (FTC). Two Phase 3 trials comparing a single-tablet regimen of BIC/TAF/FTC (50/25/200 mg) with regimens containing dolutegravir (DTG)...
-
START-ing TEMPRANO: Early Initiation of Antiretroviral Therapy for HIV
The prevailing opinion among experts regarding the optimal CD4 T-cell count at which to start patients on antiretroviral therapy (ART) has shifted several times during the evolution of HIV treatment. These shifts reflect attempts to strike a balance between preventing HIV-associated illness and...
| Day | Title |
|---|---|
|
4/24 |
Antiretroviral Update 2019
Event type: Webinars
|